Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor ...( Presentation Will be Webcast Live...),Health
Navigation Links
Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
Date:5/22/2008
Presentation Will be Webcast Live and Archived on Company's Website
ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda President and CEO will deliver a corporate presentation on Wednesday, May 28, 2008, at 9:00 a.m. Eastern Time.
The presentation will take place as part of the FBR Capital Markets 12th Annual Spring Investor Conference at the Grand Hyatt, New York, New York. Dr. Polymeropoulos' remarks will be available live on the Vanda Website, where it also will be archived for 30 days.
To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the website several minutes prior to the start of the live presentation.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is a biopharmaceutical
company focused on the development and commercialization of clinical-stage
product candidates for central nervous system disorders. The company has
three product candidates. Vanda's lead product candidate, Fanapta(TM)
(iloperidone), for which Vanda has recently submitted an NDA to the FDA, is
a compound for the treatment of schizophrenia. Vanda's second product
candidate, tasim
'/>"/>
| SOURCE Vanda Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Vanda Pharmaceuticals to Present at Natixis Bleichroeders Hidden Gems Conference
2. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
3. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
4. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
5. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
(Date:7/9/2008)...ewswire/ -- The HealthCentral,Network, Inc. (http...pConnection.com, a new online medical and peer-to-...hose struggling with obesity about,drugs, surgerie...scuss and,post questions., Three expert writers, .... Jeffrey Heit, television health reporter Amy Hen...
(Date:7/9/2008)...n that would cut $39 million from,Medicare Advanta...Newswire-USNewswire/ -- Seniors across,Mississippi...icare,Advantage program in legislation being consi...31) would cut $39 million from the Medicare Advant...back the areas where Medicare,private fee-for-serv...
(Date:7/9/2008)...n that would cut $38 million from,Medicare Advanta...ewswire-USNewswire/ -- Seniors across New Mexico,a...are Advantage program in,legislation being conside...) would cut $38 million from the Medicare Advantag...k the areas where Medicare private,fee-for-service...
(Date:7/9/2008)...a larger role in kidney transplants than previousl... well in men due to their smaller size. Women hav...Therefore, in the future, gender should be conside...esearchers from Basel and Heidelberg. , These re...ve Transplant Study", the world,s largest database...
Breaking Medicine News(10 mins):Health News:Responding to Increased Incidence of Obesity and Associated Health Issues, The HealthCentral Network Launches Site to Support those Struggling with Weight 2Health News:Mississippi Seniors Speak Out Against Medicare Advantage Cuts 2Health News:New Mexico Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Male kidneys for men only? 2[0] Responding to Increased Incidence of Obesity and Associated Health Issues, The HealthCentral Network Launches Site to Support those Struggling with Weight[0] Mississippi Seniors Speak Out Against Medicare Advantage Cuts[0] New Mexico Seniors Speak Out Against Medicare Advantage Cuts[0] Male kidneys for men only?
... offered an insight into the 'déjà vu' phenomenon,...ertain things before. // Leeds university research...ct in the memory process. Though all of us have ex...o-day life, for some people, this kind of a feelin...
...om Health Department as introduced new reforms to ...aims at giving better treatment at an affordable /... effective plan is aimed at concentration more at ... Secretary Patricia Hewitt on the new reforms as s...
...nister has promised his countrymen safe drinking w...reforms in governance are being given priority // ... India do not have access to safe drinking water. ...ters in charge of rural drinking water supply and ...
... mostly develops during young adulthood and scient...mood-altering drugs helps them to relieve of their... helps them to overcome the Manic depressive illne...lleagues from Yale’s Mood Disorder Research Progra...
Other Medicine News:Health News:Mystery Behind The Déjà Vu Phenomenon Yet To Be Resolv 2Health News:Safe Drinking Water To Be Made Available 2(Date:7/8/2008)...K, July 8 /- McGraw-Hill Professional...es for the scientific and medical,communities, tod...ectiveness reference to its comprehensive online p...//www.accesspharmacy.com ). Through an alliance wi...ases generated from clinical,studies, AccessPharma...
(Date:7/7/2008)...HCV Development Presence Includes ANA598 and ANA77...Complementary Mechanisms Conferen...- Anadys Pharmaceuticals,I...suming clinical,investigation of the Toll-Like Rec...nic hepatitis C. Based on preclinical pharmacology...
(Date:7/7/2008)...NG, July 7 /- OrbusNeich today announ...l Meeting of the Japanese Society of,Interventiona...eered R,stent has better outcomes when compared to...ione, M.D., the study,s principal,investigator and...ples,s,Division of Cardiology, Department of Clini...
(Date:7/6/2008)...e basis for CTI,s Marketing Authorization Applicat...by the EMEA, SEATTLE, July 7 /PRNewswire-FirstCal... ; MTA) today announced the publication of results...XIO(TM) (paclitaxel poliglumex,CT-2103) with gemc...performance status 2) patients with previously unt...
Breaking Medicine Technology:McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 1Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 2Cardinal Health Completes Enturia Acquisition 2043 1Cardinal Health Completes Enturia Acquisition 2043 2Federal government taps NC State experts to explain nanotech risks 5330 1Federal government taps NC State experts to explain nanotech risks 5330 2Westaim announces 2008 first quarter results 19126 1Westaim announces 2008 first quarter results 19126 2Westaim announces 2008 first quarter results 19126 3[0] McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy[0] Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV[0] Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents[0] Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
... 2007 /PRNewswire/ -- Prolexys,Pharmaceuticals and...erties of the selective small molecule anti-tumor ...company,s,chemi-proteomics technology to understan... to be published in the June 14, 2007 issue,of the...hondrial,voltage- dependent anion channels (VDACs)...
...07 /PRNewswire/ -- Two studies presented,today dem... peak,plasma levels, nor did it impair middle-of-t...n patients who suffer from chronic,insomnia. The r...nnual Meeting of the Associated Professional Sleep...ause they show that ROZEREM may be,a safe sleep me...
Other Medicine Technology:Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 2Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 2Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 4Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 5The Reusable Template is designed for use with the Brachystepper® as a guidance system for prostate brachytherapy. Please be sure that the graphics on your software match the graphics on the Reus
The MicroTouch LP (low profile) is specifically designed for use on cystoscopy tables with a fixed fluoroscopy/x-ray gantry. The MicroTouch LP attaches to tables on the side opposite the gantry and a
The Precision Stepper is the first stepper with a fully adjustable baseline. This new technology permits the physician to fine-tune the depth of the ultrasound transducer for accurate imaging and pr
The specially designed table-mounted stepper/stabilizer offers the strength and stability necessary for a flawless delivery of brachytherapy.
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |